Ind-Swift Limited (NSE:INDSWFTLTD)
15.67
-0.10 (-0.63%)
May 30, 2025, 9:29 AM IST
Ind-Swift Revenue
Ind-Swift had revenue of 1.20B INR in the quarter ending December 31, 2024, with 17.13% growth. This brings the company's revenue in the last twelve months to 5.06B, up 6.95% year-over-year. In the fiscal year ending March 31, 2024, Ind-Swift had annual revenue of 5.02B with 22.22% growth.
Revenue (ttm)
5.06B
Revenue Growth
+6.95%
P/S Ratio
0.17
Revenue / Employee
4.80M
Employees
1,054
Market Cap
847.68M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 5.02B | 913.35M | 22.22% |
Mar 31, 2023 | 4.11B | 93.73M | 2.33% |
Mar 31, 2022 | 4.02B | 420.91M | 11.70% |
Mar 31, 2021 | 3.60B | 227.98M | 6.77% |
Mar 31, 2020 | 3.37B | 417.02M | 14.13% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 525.78B |
Divi's Laboratories | 93.60B |
Cipla | 271.45B |
Apollo Hospitals Enterprise | 211.46B |
Mankind Pharma | 122.07B |
Zydus Lifesciences | 232.42B |
Aurobindo Pharma | 317.24B |
Alkem Laboratories | 127.57B |